Department of Otolaryngology-Head and Neck Surgery, McGill University, 6th Floor, McIntyre Medical Sciences Building, 3655 Promenade Sir William Osler, Montréal, QC H3G 1Y6, Canada.
Published: December 2005
AI Article Synopsis
Article Abstract
Chronic rhinosinusitis poses numerous challenges for the practitioner. This article presents strategies for making the diagnosis and managing chronic rhinosinusitis with and without nasal polyposis, and for assessing and managing disease persisting or recur-ring after endoscopic sinus surgery.
Over the past 35 years, pediatric endoscopic sinus surgery (PESS) has significantly evolved from its inception as a novel intervention to become a cornerstone in the management of pediatric sinus disorders. This evolution is reflective of a broader shift towards a more nuanced understanding and treatment of pediatric chronic rhinosinusitis (PCRS), marked by the introduction of comprehensive guidelines and the refinement of surgical indications. Recent literature and the extensive experience of the senior author, who has been at the forefront of utilizing PESS since its inception, highlight a noticeable shift in the procedure's utilization.
Background: Postoperative pain usually occur in patients who have undergone functional endoscopic sinus surgery (FESS). Remimazolam and dexmedetomidine could enhance the quality of recovery (QoR) after surgery. The aim of this study was to compare the effects of remimazolam and dexmedetomidine with respect to the QoR-40 score of patients who have undergone FESS.
Department of Otolaryngology-Head and Neck Surgery, Rhinology and Endoscopic Skull Base Surgery, American University of Beirut Medical Center, 11-0236, Riad El Solh, Beirut, 1107 2020, Lebanon.
Purpose: To investigate the risk of swallowing disorders and the frequency and intensity of vocal tract symptoms in patients with chronic rhinosinusitis and nasal polyposis (CRSwNP).
Methods: Adult patients diagnosed with CRSwNP presenting to the rhinology clinic of a tertiary referral center between March 2023 and March 2024, were recruited. Patients with acute or recent history of respiratory tract infections, tonsillitis, pharyngitis or otitis, were excluded.
Background: Chronic rhinosinusitis (CRS) is an inflammatory disease characterized by persistent immune dysregulation, which presents considerable limitations in current medical therapy.
Objects: This study investigates a supramolecular gel (PSPD), which aims to minimize systemic adverse effects through local injection, provide long-lasting anti-inflammatory effects, and modulate the mucosal immune microenvironment.
Methods: The properties of PSPD were evaluated using rheological experiments.
